DYSGERMINOMA

Clinical trials for DYSGERMINOMA explained in plain language.

Never miss a new study

Get alerted when new DYSGERMINOMA trials appear

Sign up with your email to follow new studies for DYSGERMINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Immunotherapy duo takes on resistant germ cell tumors

Disease control Ongoing

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …

Matched conditions: DYSGERMINOMA

Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC

DYSGERMINOMA

Get alerted when new DYSGERMINOMA trials appear

Immunotherapy duo takes on resistant germ cell tumors